Challenges of Interpreting Dystrophin Content by Western Blot
暂无分享,去创建一个
S. Wilton | S. Fletcher | R. Johnsen | D. Frank | F. Schnell
[1] E. Hoffman,et al. Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology , 2019, Journal of neuromuscular diseases.
[2] J. Mendell,et al. Eteplirsen treatment for Duchenne muscular dystrophy , 2018, Neurology.
[3] S. Takeda,et al. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy , 2018, Science Translational Medicine.
[4] N. Datson,et al. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy , 2018, PloS one.
[5] E. Mercuri,et al. D01 Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression in patients with genetic mutations amenable to exon 53 skipping , 2018, Neuromuscular Disorders.
[6] R. Weiss,et al. Low-level dystrophin expression attenuating the dystrophinopathy phenotype , 2017, Neuromuscular Disorders.
[7] S. Wilton,et al. P.240 Dystrophin expression in the non-DMD population: What is normal? , 2016, Neuromuscular Disorders.
[8] S. Wilton,et al. The emperor's new dystrophin: finding sense in the noise. , 2015, Trends in molecular medicine.
[9] T. Gorr,et al. Western blotting revisited: Critical perusal of underappreciated technical issues , 2015, Proteomics. Clinical applications.
[10] F. Muntoni,et al. Dystrophin quantification , 2014, Neurology.
[11] C. Farquharson,et al. A Guide to Modern Quantitative Fluorescent Western Blotting with Troubleshooting Strategies , 2014, Journal of visualized experiments : JoVE.
[12] C. Beekman,et al. A Sensitive, Reproducible and Objective Immunofluorescence Analysis Method of Dystrophin in Individual Fibers in Samples from Patients with Duchenne Muscular Dystrophy , 2014, PloS one.
[13] B. Kholodenko,et al. Evaluating Strategies to Normalise Biological Replicates of Western Blot Data , 2014, PloS one.
[14] Annemieke Aartsma-Rus. Dystrophin Analysis in Clinical Trials. , 2014, Journal of neuromuscular diseases.
[15] V. Ricotti,et al. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. , 2014, JAMA neurology.
[16] H. Kan,et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[17] K. Flanigan,et al. Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens , 2012, Neuropathology and applied neurobiology.
[18] E. Hoffman,et al. Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. , 2012, Journal of bioanalysis & biomedicine.
[19] K. Bushby,et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. , 2011, Brain : a journal of neurology.
[20] J. Bourke,et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.
[21] G. van Ommen,et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.
[22] F. Rivier,et al. Mutation spectrum leading to an attenuated phenotype in dystrophinopathies , 2005, European Journal of Human Genetics.
[23] K. Bushby,et al. Genetic and clinical correlations of Xp21 muscular dystrophy , 1992, Journal of Inherited Metabolic Disease.
[24] K. Bushby,et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy , 1993, Journal of Neurology.
[25] K. Bushby,et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy , 1993, Journal of Neurology.
[26] K. Bushby,et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis. , 1993, Journal of medical genetics.
[27] R. Waterston,et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. , 1988, The New England journal of medicine.